Avoid the Do-Over: Why Early Investment in a Scalable Manufacturing Process is Critical
Source: Thermo Fisher Scientific
By Enrico Corona, Director, Pharmaceutics & Process Technology, and Jonathan Sutch

The road to take a drug compound from discovery to commercialization is long, expensive and often fraught with unforeseen challenges. While every project will undoubtedly face some bumps along its path, far too many programs hit insurmountable obstacles that require innovators to backtrack and correct their course before proceeding, further extending timelines and adding costs.
VIEW THE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Pharmaceutical Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Thermo Fisher Scientific
This website uses cookies to ensure you get the best experience on our website. Learn more